Ratings Surperformance

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Ratings ESG MSCI

Ratings Beam Therapeutics Inc.: Strengths and Weaknesses

  • The company has a poor ESG score according to MSCI, which ranks companies by sector.
Highlights: Beam Therapeutics Inc.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • Historically, the company has been releasing figures that are above expectations.
Weaknesses: Beam Therapeutics Inc.
  • The company's earnings growth outlook lacks momentum and is a weakness.
  • Low profitability weakens the company.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Rating Financials

Beam Therapeutics Inc. SectorUnited States

Fundamentals

-

Growth

Revenue growth

EPS growth

FCF growth

Profitability

-

EBITDA Margin

-

EBIT Margin

-

Net Margin

-

Capital Efficiency

ROA

ROCE

-

ROE

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

-

Balance sheet growth

Long Term balance sheet growth

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Beam Therapeutics Inc. SectorUnited States

Global Valuation

-

Enterprise value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

More ratings

Rating Consensus

Beam Therapeutics Inc. SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Beam Therapeutics Inc. SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Beam Therapeutics Inc. SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
2.62B -
BB
- -
46.82B
AAA
39.16B -
32.9B
A
31.8B
AAA
18.85B -
B
- -
15.27B
BBB
Average 26.77B
A
Weighted average by Cap.
A
See all sector ratings
  1. Stock Market
  2. Equities
  3. BEAM Stock
  4. Ratings Beam Therapeutics Inc.